Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Recursion Pharmaceuticals (RXRX – Research Report), Edgewise Therapeutics (EWTX – Research Report) and Eledon Pharmaceuticals (ELDN – Research Report).
Recursion Pharmaceuticals (RXRX)
In a report issued on November 9, Mani Foroohar from Leerink Partners maintained a Hold rating on Recursion Pharmaceuticals, with a price target of $9.00. The company’s shares closed last Monday at $5.83, close to its 52-week low of $4.54.
According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Recursion Pharmaceuticals is a Moderate Buy with an average price target of $15.67, implying a 192.4% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Hold rating on the stock with a $10.00 price target.
See today’s best-performing stocks on TipRanks >>
Edgewise Therapeutics (EWTX)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Edgewise Therapeutics on November 9 and set a price target of $32.00. The company’s shares closed last Monday at $6.13, close to its 52-week low of $5.12.
According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Edgewise Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $27.67, implying a 415.3% upside from current levels. In a report issued on October 26, Wedbush also maintained a Buy rating on the stock with a $27.00 price target.
Eledon Pharmaceuticals (ELDN)
Leerink Partners analyst Thomas Smith reiterated a Buy rating on Eledon Pharmaceuticals on November 9 and set a price target of $7.00. The company’s shares closed last Monday at $1.20, close to its 52-week low of $1.07.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eledon Pharmaceuticals with a $15.60 average price target, which is a 1244.8% upside from current levels. In a report issued on November 3, LifeSci Capital also maintained a Buy rating on the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RXRX:
- Bayer and Recursion Focus Research Collaboration on Oncology
- Recursion Pharmaceuticals, Bayer to focus research collaboration on oncology
- Recursion enters data collection deal with Tempus, updates focus of Bayer collab
- Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
- Recursion Pharmaceuticals reports Q3 EPS (43c), consensus (38c)
